OPAT implementation bundle
“Within a Belgian, single, large community-based hospital, a multimodal intervention bundle resulted in increases in OPAT implementation, infection complexity, and required treatment durations without statistically significant differences in outcomes” Missiaen et al (2023).
OPAT osteomyelitis treatment – Full Text
“He was successfully treated with surgical debridement combined with the administration of teicoplanin plus rifampicin in the outpatient setting, completing, in total, a twelve-week course of antibiotic therapy” Papaetis et al (2023).
Role clinical microbiology laboratory in OPAT – Full Text
“Optimal care of patients requiring long-term outpatient parenteral or oral antimicrobial therapy by infectious diseases (ID) specialists is facilitated by an accurate microbiologic diagnosis” Optimal care of patients requiring long-term outpatient parenteral or oral antimicrobial therapy by infectious diseases (ID) specialists is facilitated by an accurate microbiologic diagnosis et al (2023).
OPAT management of bronchiectasis – Full Text
“This study assessed outcomes in both cystic fibrosis (CF) and non-CF bronchiectasis patients who received OPAT for the management of an acute exacerbation of bronchiectasis” Tu et al (2023).
OPAT loss to follow-up – Full Text
“We assessed factors associated with increased risk to loss of follow-up with infectious diseases staff in OPAT patients” Kaul et al (2023).
OPAT IV to oral antibiotic switch – Full Text
“Transitioning patients to oral antibiotics may be a reasonable strategy in the management of uncomplicated streptococcal BSIs” Broermann et al (2023).
Fosfomycin stability in elastomeric pump – Full Text
“The results suggest Fosfomycin eligibility for continuous infusion even in the context of outpatient parenteral antibiotic therapy” Manca et al (2023).
Australian OPAT services review – Full Text
“This is a comprehensive review of the current state of art Australian OPAT with vignettes of the types of OPAT models of care, antimicrobial prescribing and antimicrobial use” Lai et al (2023).
OPAT IV to oral antibiotic switch in orthopedic infections
“Patients transitioned to oral therapy within 4 weeks of discharge had significantly fewer adverse events and similar incidences of one-year treatment failure compared to patients maintained on parenteral vancomycin” Gallagher et al (2023).
Home infusion services in Saudi Arabia – Full Text
“A literature search was conducted via PubMed database, involving all published studies from inception until March 24th, 2023. Many studies showed positive impacts of home infusion on reducing the length of hospital stays, increasing cost-saving, and leading to high patient satisfaction” Alhifany et al (2023).
OPAT readmission rate data – Full Text
“Patients receiving OPAT at home are at increased risk for early hospital readmission, but it is often due to reasons not associated with OPAT” Bradley et al (2023).
OPAT antibiotic stability – Full Text
“In this article, we review the clinical evidence for CI in OPAT, as well as practical considerations of patient preferences, cost, and antimicrobial stability” Van Abel et al (2023).
OPAT in vulnerable patient populations – Full Text
“This is a retrospective cohort study of patients who were discharged with OPAT/COpAT through home health services over a 3-month study period” Tan et al (2023).
Ampicillin stability in elastomeric pump – Full Text
“Our data support that 15 mg/mL AMP is suitable for use in OPAT if the volume and rate of infusion are tailored to the dosage needs of antimicrobial treatments” Rodríguez-Martínez et al (2023).
Omadacycline stability in an elastomeric infusion pump – Full Text
“After reconstitution, omadacycline for injection was stable and remained within specifications for use for up to 9 days when refrigerated” Bower et al (2023).
Elastomeric infusor for combined antibiotic therapy – Full Text
“We report two cases of complex bone and joint infections involving metallo-beta-lactamase-producing Enterobacterales, successfully treated at our referral center with aztreonam and ceftazidime-avibactam for 12 weeks in continuous infusions through elastomeric infusors” Merad et al (2023).
Complex outpatient antimicrobial therapy – Full Text
“Throughout this article, the authors present a review of current literature, a proposed definition of COpAT and offer methods readers can utilize to implement an integrated COpAT/OPAT program with oral antimicrobial-specific monitoring within their current practice” Pertzborn et al (2023).
Intravenous push administration for OPAT – Full Text
“This narrative review summarizes the available data and practical implications of IVP administration of antimicrobials in the OPAT setting” Johnson et al (2023).
Temocillin stability for OPAT
“Temocillin is stable under OPAT conditions and it would be an appropriate candidate for the treatment of patients who can be discharged to complete therapy in an OPAT programme” Fernández-Rubio et al (2023).
Nephrotoxicity risk during OPAT – Full Text
“Clinicians should exercise caution when using VPT for >2 weeks, including in the OPAT setting, even when no renal dysfunction is observed during the initial week of combination therapy” Dolly et al (2023).
OPAT dalbavancin time study – Full Text
“We aim to describe the time and effort required for coordination of dalbavancin courses by outpatient registered nurses (RNs) and other outpatient parenteral antimicrobial therapy (OPAT) staff” Douglass et al (2023).
OPAT vancomycin continuous infusions
“A retrospective single centre study was conducted at a tertiary hospital on adult patients, enrolled in an outpatient parenteral antimicrobial therapy (OPAT) program, receiving vancomycin infusions for MRSA infection” Nolan et al (2023).
OPAT readmission prediction risk model – Full Text
“Further research is required to assess other predictors that can distinguish patients with higher risks of 30-day unplanned readmission in the DUHS OPAT patients” Drew et al (2023).
OPAT pharmacy residency rotation – Full Text
“A novel pharmacy residency rotation was created to meet the needs of patients enrolled in an outpatient parenteral antimicrobial therapy (OPAT) program but not yet discharged from the inpatient setting” Britt et al (2023).
OPAT for people who inject drugs in the United States – Full Text
“Outpatient parenteral antimicrobial therapy (OPAT) has been shown to be feasible for people who inject drugs (PWID) in some settings” Solomon et al (2023).
OPAT for diabetic foot osteomyelitis – Full Text
“Diabetic foot osteomyelitis (DFO) is usually treated with prolonged outpatient parenteral antibiotic therapy (OPAT)” Schechter et al (2023).
HCV treatment during OPAT – Full Text
“We found that a low proportion of patients with active hepatitis C virus (HCV) were prescribed HCV treatment by their OPAT provider and few achieved sustained virologic response” Gupta et al (2023).
OPAT to oral antibiotic switch – Full Text
“To audit the impact on cellulitis management, regimen tolerability and outcomes of switching from outpatient parenteral antimicrobial therapy (OPAT) using intravenous (i.v.) cefazolin once daily plus probenecid to oral beta-lactam therapy (OBLT) using oral flucloxacillin plus probenecid” Bowhay et al (2023).
OPAT related VTE risk assessment
“Our findings do not support universal thromboprophylaxis nor routine use of inpatient VTE risk assessment model in the OPAT setting” Durojaiye et al (2023).
Current state of OPAT in the United States – Full Text
“In this review, we will discuss the current practice patterns and patient experiences with OPAT in the United States, as well as identify future challenges and opportunities for OPAT programs” Larnard et al (2023).